心肌桥联因子1在心力衰竭中的研究进展

Research Progress of Cardiac Bridging Integrator 1 in Heart Failure

心肌桥联因子1(cardiac bridging integrator 1,cBIN1)是一种新型的心力衰竭(心衰)诊断生物标志物及心衰潜在的治疗靶点,动物试验中引入外源cBIN1基因疗法可以改善衰竭心脏的功能,延缓甚至逆转心衰的进展。心肌桥联因子1评分(cardiac bridging integrator 1 score,CS)可以评估心肌健康状况,对稳定性非卧床心衰患者具有辅助临床诊断和预测预后作用,并且支持冠状动脉微血管功能障碍可能进展为射血分数保留型心衰的假设。未来仍需进一步明确CS在早期亚临床心衰检测中的作用,并挖掘cBIN1基因靶向治疗衰竭心肌细胞cBIN1微域的潜力。

Cardiac bridging integrator 1(cBIN1)is a novel biomarker for the diagnosis of heart failure and a potential therapeutic target for heart failure.The introduction of exogenous cBIN1 gene therapy in animal studies can improve the function of the failing heart and slow or even reverse the progression of heart failure.The cBIN1 score(CS)can be used to assess myocardial health.Furthermore,it may assist in clinical diagnosis and predict prognosis in patients with stable ambulatory heart failure.Moreover,it supports the hypothesis that coronary microvascular dysfunction may progress to ejection fraction-preserved heart failure.In the future,the role of CS in early subclinical heart failure detection and the potential of cBIN1 gene for therapy targeting cBIN1 microdomains in failing cardiomyocytes should be explored.